{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:23:42Z","timestamp":1794273822589,"version":"4.9.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ymgme.2022.07.010","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T20:47:56Z","timestamp":1658868476000},"page":"49-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease"],"prefix":"10.1016","volume":"137","author":[{"given":"Dominique P.","family":"Germain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheona","family":"Altarescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Pawlaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Terryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Vujkovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2022.07.010_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","article-title":"Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group","volume":"34","author":"Gal","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0025","author":"National Organization for Rare Disorders"},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"9","key":"10.1016\/j.ymgme.2022.07.010_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000060194","article-title":"A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant","volume":"136","author":"Germain","year":"2001","journal-title":"Contrib. Nephrol."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"issue":"8","key":"10.1016\/j.ymgme.2022.07.010_bb0050","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J. Mol. Med. (Berl)."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0055","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cge.14102","article-title":"Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease","volume":"101","author":"Germain","year":"2022","journal-title":"Clin. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1666","article-title":"The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease","volume":"9","author":"Germain","year":"2021","journal-title":"Mol. Genet. Genomic Med."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0065","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"issue":"12","key":"10.1016\/j.ymgme.2022.07.010_bb0075","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000502907","article-title":"Early biomarkers of Fabry nephropathy: a review of the literature","volume":"143","author":"Riccio","year":"2019","journal-title":"Nephron."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin. Genet."},{"issue":"10","key":"10.1016\/j.ymgme.2022.07.010_bb0090","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.recesp.2017.06.028","article-title":"The p.Arg118Cys variant in the GLA gene does not cause Fabry disease. More evidence","volume":"71","author":"Barbeito-Caama\u00f1o","year":"2018","journal-title":"Rev. Esp. Cardiol. (Engl. Ed)."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2022.07.010_bb0095","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.ymgme.2022.07.010_bb0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0105","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0125","article-title":"Long-term follow-up of renal function in patients treated with migalastat for Fabry disease","volume":"28","author":"Bichet","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"9","key":"10.1016\/j.ymgme.2022.07.010_bb0130","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0135","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0140","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"issue":"10","key":"10.1016\/j.ymgme.2022.07.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2019.103702","article-title":"Why systematic literature reviews in Fabry disease should include all published evidence","volume":"62","author":"Elliott","year":"2019","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0150","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ymgme.2018.04.004","article-title":"Therapeutic goals in Fabry disease: recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy","volume":"126","author":"Wanner","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"National Institutes of Health Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.ymgme.2022.07.010_bb0170","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/gim.2013.56","article-title":"Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa","volume":"15","author":"Schiffmann","year":"2013","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0175","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0180","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0190","first-page":"95","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep."},{"issue":"13","key":"10.1016\/j.ymgme.2022.07.010_bb0195","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2174\/0929867324666170616102112","article-title":"Biomarkers for diagnosing and staging of Fabry disease","volume":"25","author":"Kramer","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/TCRM.S247814","article-title":"Diagnosis and screening of patients with Fabry disease","volume":"16","author":"Vardarli","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0205","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2021","journal-title":"J. Med. Genet."},{"issue":"8","key":"10.1016\/j.ymgme.2022.07.010_bb0210","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","article-title":"Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy","volume":"56","author":"Lenders","year":"2019","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0215","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jimd.12167","article-title":"Fabry disease genotype, phenotype, and migalastat amenability: insights from a national cohort","volume":"43","author":"Nowak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0220","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"M\u00fcntze","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omtm.2020.08.012","article-title":"In vitro and in vivo amenability to migalastat in Fabry disease","volume":"19","author":"Lenders","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"8","key":"10.1016\/j.ymgme.2022.07.010_bb0230","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","article-title":"Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy","volume":"56","author":"Lenders","year":"2019","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0235","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2022.07.010_bb0240","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"21","key":"10.1016\/j.ymgme.2022.07.010_bb0245","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.3390\/ijms21218080","article-title":"Biomarkers in Anderson-Fabry disease","volume":"21","author":"Simonetta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0250","series-title":"Fabrazyme powder for concentrate for solution for infusion SmPC","author":"Sanofi","year":"2021"},{"key":"10.1016\/j.ymgme.2022.07.010_bb0255","series-title":"Replagal concentrate for solution for infusion SmPC. Last updated 20 Jul","author":"Takeda","year":"2021"},{"issue":"9","key":"10.1016\/j.ymgme.2022.07.010_bb0260","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"21","key":"10.1016\/j.ymgme.2022.07.010_bb0265","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0270","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2125.2009.03501.x","article-title":"Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies","volume":"68","author":"Tesmoingt","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0275","first-page":"109","article-title":"Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy","volume":"5","author":"Nicholls","year":"2012","journal-title":"JIMD Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0280","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0285","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0290","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0295","doi-asserted-by":"crossref","DOI":"10.1177\/2326409816661352","article-title":"Cardiac manifestation of Fabry disease: from hypertrophic cardiomyopathy to early diagnosis and treatment in patients without left ventricular hypertrophy","volume":"4","author":"Fern\u00e1ndez","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0300","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0305","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view","volume":"112","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0315","doi-asserted-by":"crossref","DOI":"10.1186\/s12947-019-0151-5","article-title":"Role of cardiac imaging in Anderson-Fabry cardiomyopathy","volume":"17","author":"Serra","year":"2019","journal-title":"Cardiovasc. Ultrasound"},{"issue":"12","key":"10.1016\/j.ymgme.2022.07.010_bb0320","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-\u03b2: data from the Fabry registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2022.07.010_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0330","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjcard.2011.09.052","article-title":"Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease","volume":"109","author":"Namdar","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0335","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007168","article-title":"Cardiac phenotype of prehypertrophic Fabry disease","volume":"11","author":"Nordin","year":"2018","journal-title":"Circ. Cardiovasc. Imaging."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0340","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.stemcr.2019.07.004","article-title":"A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology","volume":"13","author":"Birket","year":"2019","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0345","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2021.06.032","article-title":"Recognition of pre-hypertrophic cardiac involvement in Fabry disease based on automated electrocardiographic measures","volume":"338","author":"Namdar","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0350","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2021.07.022","article-title":"ECG-based score estimates the probability to detect Fabry disease cardiac involvement","volume":"339","author":"Figliozzi","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0355","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ymgme.2022.07.010_bb0360","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009013","article-title":"Multimodality imaging assessment of Fabry disease","volume":"12","author":"Tower-Rader","year":"2019","journal-title":"Circ. Cardiovasc. Imaging."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0365","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0370","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0375","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of clinical evolution in prehypertrophic Fabry disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ. Cardiovasc. Imaging."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0380","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/heartjnl-2018-313699","article-title":"Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease","volume":"105","author":"Vijapurapu","year":"2019","journal-title":"Heart."},{"issue":"7","key":"10.1016\/j.ymgme.2022.07.010_bb0385","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.008872","article-title":"Quantitative myocardial perfusion in Fabry disease","volume":"12","author":"Knott","year":"2019","journal-title":"Circ. Cardiovasc. Imaging."},{"issue":"7","key":"10.1016\/j.ymgme.2022.07.010_bb0390","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2022.07.010_bb0395","article-title":"T1 mapping in patients with Fabry disease predicts functional and morphological abnormalities in cardiac MRI","volume":"41","author":"Gatterer","year":"2020","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0400","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial edema, myocyte injury, and disease severity in Fabry disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ. Cardiovasc. Imaging."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0405","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007019","article-title":"Early cardiac involvement affects left ventricular longitudinal function in females carrying \u03b1-Galactosidase a mutation: role of hybrid positron emission tomography and magnetic resonance imaging and speckle-tracking echocardiography","volume":"11","author":"Spinelli","year":"2018","journal-title":"Circ. Cardiovasc. Imaging."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0410","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjcard.2012.08.055","article-title":"Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with Anderson-Fabry disease","volume":"111","author":"Coats","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ymgme.2022.07.010_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140627","article-title":"Left ventricular geometry and blood pressure as predictors of adverse progression of Fabry cardiomyopathy","volume":"10","author":"Kr\u00e4mer","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091757","article-title":"Continuous cardiac troponin I release in Fabry disease","volume":"9","author":"Feustel","year":"2014","journal-title":"PLoS One"},{"issue":"8 Pt 2","key":"10.1016\/j.ymgme.2022.07.010_bb0425","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000803","article-title":"Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease","volume":"5","author":"Liu","year":"2018","journal-title":"Open Heart."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0435","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002839","article-title":"High-sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in Fabry disease","volume":"5","author":"Seydelmann","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0440","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: a review \u2013 how can we optimize the management of Fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0445","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/ki.2008.522","article-title":"Renal manifestations in Fabry disease and therapeutic options","volume":"111","author":"Torra","year":"2008","journal-title":"Kidney Int. Suppl."},{"issue":"Pt 3","key":"10.1016\/j.ymgme.2022.07.010_bb0450","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1258\/acb.2009.009007","article-title":"How should proteinuria be detected and measured?","volume":"46","author":"Lamb","year":"2009","journal-title":"Ann. Clin. Biochem."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0455","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-012-2222-9","article-title":"Renal complications of Fabry disease in children","volume":"28","author":"Najafian","year":"2013","journal-title":"Pediatr. Nephrol."},{"issue":"7","key":"10.1016\/j.ymgme.2022.07.010_bb0460","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2169\/internalmedicine.3813-19","article-title":"Urinary mulberry cells as a biomarker of the efficacy of enzyme replacement therapy for Fabry disease","volume":"59","author":"Aoyama","year":"2020","journal-title":"Intern. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0465","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0470","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120985627","article-title":"Renal manifestations of Fabry disease: a narrative review","volume":"8","author":"Silva","year":"2021","journal-title":"Can. J. Kidney Health Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2022.07.010_bb0475","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0480","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0485","doi-asserted-by":"crossref","first-page":"683","DOI":"10.21037\/cdt-20-743","article-title":"Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review","volume":"11","author":"Oder","year":"2021","journal-title":"Cardiovasc. Diagn. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0490","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pcd.2018.02.001","article-title":"SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis","volume":"12","author":"Seidu","year":"2018","journal-title":"Prim Care Diab."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0495","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2022.07.010_bb0500","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.ymgme.2022.07.010_bb0505","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0510","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease: current status of knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke."},{"issue":"20","key":"10.1016\/j.ymgme.2022.07.010_bb0515","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1212\/WNL.0000000000002673","article-title":"Determinants of white matter hyperintensity burden in patients with Fabry disease","volume":"86","author":"Rost","year":"2016","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0520","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00415-020-10209-7","article-title":"MRI-visible perivascular spaces as an imaging biomarker in Fabry disease","volume":"268","author":"Lyndon","year":"2021","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0525","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3174\/ajnr.A5069","article-title":"Basilar artery changes in Fabry disease","volume":"38","author":"Manara","year":"2017","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"7","key":"10.1016\/j.ymgme.2022.07.010_bb0530","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jnnp-2019-322268","article-title":"Determinants of cerebral radiological progression in Fabry disease","volume":"91","author":"K\u00f6rver","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymgme.2022.07.010_bb0535","article-title":"Stroke and chronic kidney disease in Fabry disease","volume":"105423","author":"Tapia","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0540","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jocn.2019.03.064","article-title":"Fabry\u2019s disease and stroke: effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis","volume":"65","author":"Sheng","year":"2019","journal-title":"J. Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0545","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10545-007-0616-9","article-title":"Natural history of the respiratory involvement in Anderson-Fabry disease","volume":"30","author":"Magage","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0550","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0555","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1076\/opge.24.3.129.15609","article-title":"Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients","volume":"24","author":"Orssaud","year":"2003","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0560","first-page":"45","article-title":"Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta: data from the Fabry registry","volume":"38","author":"Wilcox","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0565","article-title":"Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: a Fabry registry analysis stratified by phenotype","volume":"25","author":"Hopkin","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0570","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18063320","article-title":"Gastrointestinal involvement in Anderson-Fabry disease: a narrative review","volume":"18","author":"Caputo","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0575","doi-asserted-by":"crossref","first-page":"12010","DOI":"10.1038\/s41598-019-48426-4","article-title":"Lyso-Gb3 modulates the gut microbiota and decreases butyrate production","volume":"9","author":"Aguilera-Correa","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0580","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0585","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.ymgme.2022.07.010_bb0590","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0595","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch","volume":"25","author":"Weidemann","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0600","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1681\/ASN.2015030337","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.ymgme.2022.07.010_bb0605","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages","volume":"33","author":"Kr\u00e4mer","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0610","first-page":"173","article-title":"Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America","volume":"77","author":"Ripeau","year":"2017","journal-title":"Medicina (B Aires)."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0615","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40360-017-0152-7","article-title":"Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-na\u00efve Fabry disease patients","volume":"18","author":"Tsuboi","year":"2017","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0620","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0625","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0630","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"3","key":"10.1016\/j.ymgme.2022.07.010_bb0635","first-page":"825","article-title":"Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. ESC","volume":"7","author":"Wanner","year":"2020","journal-title":"Heart Fail."},{"issue":"8","key":"10.1016\/j.ymgme.2022.07.010_bb0640","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup","volume":"57","author":"Germain","year":"2020","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0645","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ckj\/sfw082","article-title":"FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease","volume":"9","author":"Mignani","year":"2016","journal-title":"Clin. Kidney J."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0650","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ckj\/sfy108","article-title":"New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases","volume":"12","author":"Mignani","year":"2019","journal-title":"Clin. Kidney J."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0655","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ckj\/sfy126","article-title":"Will the FAbry STabilization indEX make its way to everyday clinical practice?","volume":"12","author":"Cairns","year":"2019","journal-title":"Clin. Kidney J."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0660","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0665","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0670","first-page":"S188","article-title":"Differential effects of agalsidase alfa and agalsidase beta in Fabry outcomes: 10 year outcomes from the Canadian Fabry disease initiative","volume":"41","author":"Sirrs","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0675","series-title":"Galafold 123 Mg Hard Capsules - Sumamry of Product Characteristics","author":"Ltd ATE","year":"2019"},{"issue":"11","key":"10.1016\/j.ymgme.2022.07.010_bb0680","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2022.07.010_bb0685","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/ckj\/sfaa227","article-title":"Fabry disease and COVID-19: international expert recommendations for management based on real-world experience","volume":"13","author":"Laney","year":"2020","journal-title":"Clin. Kidney J."},{"issue":"1","key":"10.1016\/j.ymgme.2022.07.010_bb0690","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ndt\/gfaa314","article-title":"Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA","volume":"36","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0695","article-title":"Severe manifestations and treatment of COVID-19 in a transplanted patient with Fabry disease","volume":"29","author":"Mahoney","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2022.07.010_bb0700","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ndt\/gfac007","article-title":"Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study","volume":"37","author":"Quiroga","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.ymgme.2022.07.010_bb0705","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/vaccines9121412","article-title":"Humoral immune response to SARS-CoV-2 vaccination after a booster vaccine dose in two kidney transplant recipients with Fabry disease and variable secondary immunosuppressive regimens","volume":"9","author":"Bernea","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.ymgme.2022.07.010_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115412","article-title":"Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress","volume":"414","author":"Greg\u00f3rio","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4\u20136","key":"10.1016\/j.ymgme.2022.07.010_bb0715","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/01913123.2020.1850966","article-title":"Zebra-like bodies in COVID-19: is phospholipidosis evidence of hydroxychloroquine induced acute kidney injury?","volume":"44","author":"Obeidat","year":"2020","journal-title":"Ultrastruct. Pathol."},{"issue":"4","key":"10.1016\/j.ymgme.2022.07.010_bb0720","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2020.06.002","article-title":"Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued","volume":"130","author":"Politei","year":"2020","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222003705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222003705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:53:22Z","timestamp":1761090802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719222003705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":144,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1096719222003705"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.07.010","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}